To evaluate the efficacy of neoadjuvant chemoimmunotherapy compared to neoadjuvant immunotherapy alone in patients with resectable head and neck squamous cell carcinoma (HNSCC).
Key Findings:
Pooled MPR plus CPR rates were 66% for chemoimmunotherapy, 18% for dual-agent immunotherapy, and 6% for single-agent immunotherapy.
CPR rates were 38%, 5%, and approximately 3% for the respective treatment groups.
Radiographic response rates favored chemoimmunotherapy with 66% showing partial or complete responses compared to 9% and 6% for dual-agent and single-agent immunotherapy, respectively.
Adverse events (grade 3 to 5) occurred in 17% of patients receiving chemoimmunotherapy, 3% for dual-agent, and 29% for single-agent immunotherapy.
Interpretation:
Limitations:
Many included trials were single-group studies, limiting direct comparisons.
High heterogeneity across chemoimmunotherapy trials.
Subgroup analyses by disease subsite, stage, or HPV status could not be performed.
Inconsistent reporting of survival outcomes and adverse events.
